Table 2.
Clinical outcomes of patients in the study
| All tested patients | Any virus detected | No virus detected | A/H1 | A/H3 | INF-B | RSV | hMPV | PIV | |
|---|---|---|---|---|---|---|---|---|---|
| LOS (days) Median (IQR) | 5 (2–9) | 4 (2–8) | 5 (3–11) | 5 (3–8)* | 4 (2–7)^ | 3 (2–6)^ | 5 (3–18)* | 4 (2–7)^ | 3 (2–9) |
| ICU admission | 325 (18.6%) | 68 (12.1%) | 257 (21.6%) | 19 (29.2%)* | 18 (10.2%)^ | 8 (10.4%)^ | 11 (10.9%)^ | 5 (6.0%)^ | 7 (10.3%)^ |
| Ventilation | 209 (11.9%) | 38 (6.8%) | 171 (14.4%) | 10 (15.4%)* | 11 (6.2%)^ | 6 (7.8%) | 5 (5.0%)^ | 1 (1.2%)^ | 4 (5.9%) |
| ICU (hours) Median (IQR) | 120 (56–241) | 115 (52–265) | 120 (56–240) | 97 (40–502) | 119 (48–256) | 201 (47.5–360) | 120 (61–136) | 111 (97–152) | 97 (62–236) |
| Ventilation (hours) Median (IQR) | 145 (86–262) | 165 (91–467) | 139 (83–240) | 438.5 (147–759) | 141 (90–358) | 285 (91–379) | 129 (102–159) | 75 (75–75) | 157.5 (96.5–173.5) |
| Pneumonia | 775 (44.2%) | 234 (41.6%) | 541 (45.5%) | 40 (61.5%)* | 64 (36.2%)^ | 23 (29.9%)^ | 42 (41.6%)^ | 35 (41.7%)^ | 22 (48.5%) |
| Deceased | 89 (5.1%) | 14 (2.5%) | 75 (6.3%) | 2 (3.1%) | 5 (2.8%) | 3 (3.9%) | 3 (3.0%) | 1 (1.2%) | 0 (0%) |
*Statistically significant difference compared to A/H3 in univariate analysis. ^Statistically significant difference compared to A/H1 in univariate analysis.